EGFR and non-small cell lung carcinoma: Molecular targeted therapy represented by epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) can significantly prolong the overall survival (OS) of patients and has been approved for the first-line treatment of advanced NSCLC patients with positive EGFR gene mutation [28,29,30,31].